Published: 9 July 2020
Author(s): Rafael Dal-Ré, Ignacio Mahillo-Fernández
Section: Letter to the Editor

Amid huge efforts to address the therapeutic uncertainties clinicians are facing with COVID-19 patients’ management, many clinical trials are badly designed [1]. Trials with no control group and with planned sample sizes of ≤100 participants are examples of poor research [1]. However, the need to conduct well designed trials that could provide robust findings is a must, from both the scientific and ethical perspectives [2]. The quality of a trial relates to the design, conduct, analysis and reporting.


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.